Link Health Group of Guangzhou in-licensed China rights to Lidoderm®, a lidocaine patch product aimed at pain associated with post-herpetic neuralgia. Teikoku Pharma of San Jose, California, a subsidiary of Japan’s Teikoku Seiyaku, developed the product. Link will have China rights to develop, market and distribute Lidoderm, which is described as TPU’s flagship offering, a combination of lidocaine and a soft hydrogel plaster. Lidoderm in approved in the US and EU under the name Versatis®.
Source: China Biotoday
